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The discovery of Helicobacter pylori  has already 
changed the natural history of peptic ulcer disease, with 
most patients being cured at their ﬁ  rst presentation. 
Similarly, the incidence of gastric cancer and other 
diseases related to H. pylori  are likely to be greatly 
reduced in the near future. Isolation of the spiral intra-
gastric bacterium H. pylori  totally reversed the false 
dogma that the stomach was sterile, and it taught us that 
chronic infectious disease can still exist in modern soci-
ety. Helicobacter pylori’s unique location, persistence, 
and evasion of the immune system offer important in-
sights into the pathophysiology of the gut. Also, the fact 
that it was overlooked for so long encourages us to 
think “outside the box” when investigating other dis-
eases with obscure etiologies. We should consider such 
provocative scientiﬁ  c ideas as bridges to the future dis-
ease control.
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Introduction
Background
In recent years, research groups have concentrated on 
the molecular structures whereby Helicobacter pylori 
survives in the hostile gastric environment and persists 
in spite of the host’s immune response. Epidemiologic 
studies have also provided convincing evidence that H. 
pylori is associated not only with gastroduodenal dis-
eases, including chronic gastritis, peptic ulcer diseases, 
low-grade gastric mucosa-associated lymphoid tissue 
(MALT) lymphoma, and noncardiac gastric adenocar-
cinoma,1–6 but also with extragut diseases.7–12
The initial advance that facilitated the explosion of 
research related to H. pylori was the development of 
microaerobic cultivation methods for this bacterium. 
Then, it was shown that intentional infection of a vol-
unteer led to gastritis.13 Classical bacteriology demon-
strated that H. pylori  is a Gram-negative, ﬂ  agellated 
organism that produces a number of enzymes, including 
catalase and urease, which help neutralize host respons-
es and favor colonization.14,15 One of the early beneﬁ  ts 
gained from this basic research was the demonstration 
that urease is produced by virtually all strains of H. py-
lori. This led to the development of accurate diagnostic 
tests, including the rapid urease test and the urea breath 
test. A stool antigen test has also emerged as an infor-
mative, noninvasive means by which to diagnose infec-
tion via detection of bacterial antigen.16 In addition, the 
ability to culture H. pylori provided a diagnostic test 
that allowed assessment of antibiotic susceptibility.
Before the modern discovery of intragastric bacteria 
25 years ago,17 several reports dealt with spiral gastric 
bacteria as long ago as 1890. The modern discovery of 
H. pylori  might have been delayed because in 1954, 
Palmer18 denied the existence of microorganisms in the 
human stomach, claiming that spiral bacteria were seen 
only post-mortem because microorganisms could not 
survive in the acidic gastric environment. However, mi-
croorganisms had been described in the gastric mucosa 
since the 1890s.19  For example, in Japan, Kasai and 
Kobayashi20 of the Kitasato Institute reported propaga-
tion of a spirochete-like organism, probably Helico-
bacter felis, from the stomach of dogs and cats, but not 
from laboratory animals (Fig. 1). They showed that 
when rabbits infected with these spirochetes were also 
inoculated with the virus ﬁ  xe (attenuated rabies virus), 
marked hemorrhagic lesions occurred in the gastric mu-
cosa.20 They also demonstrated that spirochetes inocu-
lated into the gastric mucosa of the mouse could be 
eradicated by arsaminol20 (a modern equivalent of ars-
aminol is thought to be bismuth, a close relative of ar-
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senic).21,22 Seventy years then elapsed before scientists 
again attempted to treat gastric diseases associated with 
“spirochetes,” that is, Helicobacter infection.
Present status
Epidemiology
Most new H. pylori infections occur in children; how-
ever, in the absence of speciﬁ  c clinical signs associated 
with infection, the mode of transmission is difﬁ  cult to 
deﬁ  ne. Vomitus, saliva, and feces are the presumed 
sources of direct transmission, particularly in crowded 
housing conditions. Generally, infection correlates in-
versely with socioeconomic conditions,23 with lifetime 
infection rates in afﬂ  uent countries dropping toward 
10%, while rates in countries with emerging economies 
approach 80%–90%.16,24,25  Most infected individuals 
experience asymptomatic gastritis, although recurrent 
gastroduodenal ulceration may occur in 10%–15% of 
the infected population. The incidence of gastric cancer 
is lower, with approximately 1%–5% of infected indi-
viduals developing adenocarcinoma and even fewer ex-
periencing gastric MALT lymphoma.1,2,26–29
Initially H. pylori depends on its urease enzyme to 
survive in an acid environment, and then on its spiral 
shape and motility to reach the gastric epithelium, 
where it sticks to cells through the various speciﬁ  c adhe-
sion molecules. Once attached, most organisms then 
deliver damaging toxins to the mucosa.
Pathogenesis
The most investigated of these toxins stem from a seg-
ment of bacterial DNA referred to as the cag pathoge-
nicity island (cag PAI). The presence of the cag PAI 
is usually associated with presence of the s1m1 (more 
harmful) subtype of the vacuolating cytotoxin VacA. 
Genes within the cag  PAI encode proteins such as 
CagE, an ATPase that drives a type IV secretion appa-
ratus that allows bacterial macromolecules, especially 
CagA toxin, to translocate into the host cell.3,30 The in-
tact cag PAI of H. pylori plays a signiﬁ  cant role in the 
pathogenesis of gastritis in humans, since H. pylori 
carrying the cag  PAI is associated with increased 
chemokine expression in gastric mucosal specimens31 
and stronger inﬂ  ammation.
CagA is injected into epithelial cells by the type IV 
secretory system, possibly as a mechanism to reduce the 
stress of gastric acid on the bacterium, since its tran-
scription is increased at low pH.32  VacA is a pore-
forming protein, which causes epithelial cells to vacuolate 
in vitro. Retrospective analyses of samples from gastric 
cancer patients have suggested an association with the 
cagA+/vacA+-positive genotype.33 Further studies have 
conﬁ  rmed that a risk for both cancer and peptic ulcer is 
associated particularly with the cagA/vacA s1m1 geno-
type, but rarely with strains carrying the vacA s2m2 
polymorphism.34,35 However, the cagA gene does not act 
alone, because delivery of the CagA protein into epithe-
lial cells appears to be dependent on a secretion system 
encoded for by the adjacent cluster of genes, the cag 
PAI.36 After the CagA protein is injected into the host 
cell cytoplasm, it is tyrosine phosphorylated by host Src 
kinases and subsequently changes the epithelial mor-
phology.37–41 CagA in strains from distinct geographic 
populations appears to be phosphorylated to a different 
degree, resulting in graded effects on intracellular 
signaling.42,43
Oxygen-derived free radicals, which are released 
from activated neutrophils, are considered to be one of 
the potential toxic factors involving H. pylori-induced 
gastric mucosal injury, since H. pylori exhibits chemo-
tactic activity for neutrophils.44,45 Neutrophil inﬁ  ltration 
of the gastric mucosa leads to development of the initial 
lesion in H. pylori–associated gastritis and remains a 
hallmark of active bacterial infection. In response to the 
activation of neutrophils, NADPH oxidase (Nox) in 
the neutrophils’ cell membranes becomes activated; an 
electron transfer takes place from NADPH in cells to 
Fig. 1.  Rokuzo Kobayashi (1887–1969), at his desk in the 
ofﬁ  ce of Keio University, Tokyo, Japan. Photo taken in 1935. 
Adopted from “Kobayashi Rokuzo” published by Dr. 
Rokuzo Kobayashi Memorial Association, 1971H. Suzuki et al.: Consensus for H. pylori infection in Japan  3
oxygen inside and outside of cells, and the oxygen mol-
ecules that receive an electron become superoxide radi-
cals (O2
−), which are rapidly converted to hydrogen 
per oxides  (H2O2) by spontaneous dismutation, or to 
enzymatic superoxide dismutase (SOD) and hydroxyl 
radicals (•OH), which are formed nonenzymatically in 
the presence of Fe2+. In neutrophils, myeloperoxidase 
(MPO) also results in the formation of a potent oxidant, 
the hypochlorous anion (OCl−), from H2O2  in the 
presence of Cl−. This hypochlorous anion reacts with 
ammonia, derived from urea by H. pylori-associated 
urease, and yields cytotoxic oxidant, monochloramine 
(NH2Cl)46  with its lipophilic property, allowing it to 
freely penetrate biological membranes to oxidize intra-
cellular components47 (Fig. 2).
8-Hydroxy-2-deoxyguanosine (8-OHdG) is one of 
the most abundant lesions in DNA induced by reactive 
oxygen species.48 It results from an attack by a singlet 
hydroxyl or oxygen radical on guanine (Fig. 2). Patients 
with  cagA-positive  H. pylori  strains have higher 
8-OHdG levels than both cagA-negative and H. 
pylori-negative patients.49  The  cagA-positive patients 
are characterized by greater oxidative DNA damage 
overall and at a younger age, in the presence of multifo-
cal atrophy.49
The preferred animal model for studying H. pylori 
gastritis is the Mongolian gerbil (Meriones unguicula-
tus).50–53 In one study, gerbils infected with a mutated 
strain lacking cagE  exhibited a substantially reduced 
severity of gastritis.54 Gastric ulceration developed in all 
of the gerbils infected with the wild-type strain but in 
none of those infected with the cagE mutant strain. In 
addition, intestinal metaplasia and gastric cancer devel-
oped in some gerbils with wild-type infection but not in 
animals infected with the cagE-negative mutant.54 These 
ﬁ  ndings were conﬁ  rmed by showing that the repaired 
cagE-positive  H. pylori  strain induced severe gastric 
inﬂ  ammation, gastric mucosal atrophy, and gastric ulcer 
formation.55  Recently, the nucleotide sequences of 
cDNAs encoding preproghrelin, a precursor of ghrelin 
(an appetite-promoting endocrine peptide produced 
mainly from A-like cells in the gastric fundus)52,56 and 
sonic hedgehog, a morphogen that may regulate and 
organize fundic gland epithelial differentiation, have 
been identiﬁ  ed in the Mongolian gerbil.53,57 Preproghre-
lin and sonic hedgehog mRNA expression is signiﬁ  -
cantly reduced in the gastric mucosa of Mongolian 
gerbils with persistent H. pylori colonization.52,53
After reaching the mucosa and attaching by means of 
its lectins, H. pylori applies toxin to the gastric mucosa 
(Fig. 3). Then, the cells change their morphology and 
migrate, some detach, and sometimes apoptosis occurs. 
The healing process involves proliferation of adjacent, 
more healthy cells. Gastric epithelial cell turnover is 
regulated by the balance between cell death (apoptosis) 
and cell proliferation (Fig. 3). Such a regulated cell 
turnover by apoptosis and proliferation is essential 
for maintaining healthy gastric mucosal integrity. 
Some cells differentiate into intestinal tissue, a transfor-
mation called intestinal metaplasia. This may be some-
what protective in that H. pylori is unable to attach to 
these cells, allowing inﬂ  ammatory processes to become 
quiet in these areas. However, extensive metaplasia is 
associated with decreased acid secretion, which may al-
low other commensal bacteria to colonize and carcino-
gen formation to occur. Proliferation by itself is not 
carcinogenic, but mutagens, such as monochloramine, 
may be formed in the presence of ammonia and hypo-
























Fig. 2.  Helicobacter pylori-associated gas-
tric oxidative injury: monochloramine 
pathway. MPO, myeloperoxidase; SOD, 
superoxide dismutase4  H. Suzuki et al.: Consensus for H. pylori infection in Japan
At an earlier phase after bacterial inoculation, an 
initial transient enhancement of cell apoptosis (2–4 
weeks) and a later increase in cell proliferation (16–20 
weeks) occur in the H. pylori-colonized gastric mucosa 
of gerbils.58 While the level of apoptosis increases as 
H. pylori-evoked gastric mucosal inﬂ  ammation 
advances in mice, the enhanced level of apoptosis is 
signiﬁ  cantly attenuated in H. pylori-colonized gastric 
mucosa of gerbils with enhanced inﬂ  ammation and epi-
thelial proliferation in the gastric mucosa during 
longer term colonization,59  suggesting a possible link 
between attenuated gastric mucosal apoptosis and a 
speciﬁ  c carcinogenesis in gerbils after H. pylori 
colonization.60,61
Peptic ulcer disease
The strongest association of H. pylori infection is with 
peptic ulcer disease;62 95% of duodenal ulcers and 70% 
of gastric ulcers are related to H. pylori infection. Sev-
eral cohort studies have estimated that the lifetime risk 
of ulcer disease in H. pylori-positive subjects is three to 
ten times that in H. pylori-negative subjects.63 Introduc-
tion of H. pylori eradication regimens has completed 
the evidence for a causal relation between H. pylori and 
peptic ulcer disease because H. pylori eradication has 
been shown to strongly reduce the risk of ulcer recur-
rence.64 In prospective controlled studies of duodenal 
ulcer recurrence, ulcers recurred in 55%–86% of pa-
tients in H. pylori-positive cohorts, in contrast to a rate 
of 3%–21% in H. pylori-negative (successfully eradi-
cated) cohorts65–70 (Table 1). Gastric ulcers typically re-
curred in 46%–71% of patients in H. pylori-positive 
cohorts, contrasting with ulcer recurrence rates of 10% 
or less in H. pylori-negative (successfully eradicated) 
cohorts71–76 (Table 2).
The meta-analytic results of a North American study 
by Laine et al.70 have shown that H. pylori eradication 
markedly decreases ulcer recurrence. Nevertheless, ul-
cers recurred in 20% of patients in these studies within 
6 months, despite a successful cure of infection and no 
reported use of nonsteroidal anti-inﬂ  ammatory drugs 
(NSAIDs), suggesting that non-H. pylori, non-NSAID 
ulcers may be more common in the United States than 
previously believed.
According to a recent systematic review of 56 ran-
domized controlled trials of treatment for peptic ulcer 
disease in H. pylori-positive adults,77 a 1 to 2 weeks’ 
course of H. pylori eradication therapy is an effective 









Fig. 3.  After reaching the mucosa and at-
taching by means of its lectins, H. pylori 
applies toxin to the gastric mucosa. Cells 
change their morphology and migrate, 
some detach, and sometimes apoptosis 
occurs. The healing process involves pro-
liferation of adjacent, more healthy cells. 
Proliferation by itself is not carcinogenic, 
but mutagens, such as monochloramine, 
may be formed in the presence of am-
monia and hypochlorous anion. These 
cause errors in transcription. Some cells 
differentiate into intestinal tissue, a trans-
formation called intestinal metaplasia
Table 1.  Duodenal ulcer recurrence rate 1 year after H. pylori eradication
    Noneradication Eradication
    group group
Authors  Year  % (95% CI)  % (95% CI)  P value
Marshall et al.66  1988 55  (34–75)      21  (3–40)   0.029
Hentschel et al.65  1993 86  (76–96)        8  (0.4–15)  <0.001
Penston67  1994 67  (62–72)        7  (5–10) —
Tytgat68  1995 58  (55–61)  2.6  (2–4)  —
Hopkins et al.69  1996  67 (63–72)       6  (4–9)   0.002
Laine et al.70  1998 56  (50–61)      20  (14–24)  <0.001
CI, conﬁ  dence intervalH. Suzuki et al.: Consensus for H. pylori infection in Japan  5
eradication therapy was superior to several weeks of 
ulcer healing drugs [34 trials, 3910 patients, relative risk 
(RR) of ulcer persisting = 0.66] or no treatment (2 trials, 
207 patients, RR = 0.37). In gastric ulcer (GU) healing, 
no signiﬁ  cant differences were detected between eradi-
cation therapy and administration of an ulcer healing 
drug (14 trials, 1572 patients, RR = 1.25). For prevent-
ing DU recurrence, no signiﬁ  cant differences were de-
tected between eradication therapy and maintenance 
therapy with an ulcer healing drug (4 trials, 319 patients, 
RR  =  0.73), but eradication therapy was superior to 
no treatment (27 trials, 2509 patients, RR = 0.20). For 
preventing GU recurrence, eradication therapy was 
superior to no treatment (11 trials, 1104 patients, RR = 
0.29).
The incidence of peptic ulcers has steadily decreased 
in Western countries in the last two decades. The de-
creasing prevalence of peptic ulcers is thought to result 
both from contraction of the formerly large pool of pa-
tients with recurrent ulcer disease by H. pylori eradica-
tion at ﬁ  rst presentation and from the decreasing 
prevalence of H. pylori infection in the population.24,78,79 
The latter is related to several factors, such as improved 
hygiene and living conditions, decreased family sizes, 
and the use of antimicrobial therapy for other 
purposes.
Helicobacter pylori and NSAIDs are the two major 
causes of peptic ulcer disease. Their potential interac-
tion in the induction of ulcer disease remains controver-
sial. A thorough analysis of interaction data has revealed 
that the ulcer-inducing effects of both risk factors are 
cumulative.80 Eradication of H. pylori in chronic NSAID 
users does no harm, and in some studies has decreased 
the incidence of ulcer disease. In a study from Hong 
Kong, patients starting with NSAID maintenance ther-
apy were randomized to eradication therapy or placebo. 
After 6 months of follow-up, the incidence of ulcers was 
12.1% in the eradication group and 34.4% in the place-
bo group (P = 0.0085). The corresponding probabilities 
of complicated ulcers after 6 months were 4.2% and 
27.1% (P  =  0.0026), respectively.81  These data show 
that, at least in an Asian population, screening and 
treatment for H. pylori infection signiﬁ  cantly reduces 
the risk of ulcers in patients starting long-term NSAID 
treatment, but also that eradication alone is insufﬁ  cient 
to totally prevent ulcers and ulcer complications. In 
several studies, H. pylori  eradication was inferior to 
omeprazole maintenance treatment for prevention of 
recurrent NSAID-associated ulcer bleeding.82,83  An 
overall synthesis of these data suggests that NSAIDs 
and H. pylori are independent, but not necessarily ad-
ditive, causes of peptic ulcer. The wise choice might be 
to address both issues in all patients with ulcer compli-
cations: supplement NSAID users at risk with a second 
agent, consider the option of selective cyclooxygenase-2 
(cox-2) inhibitors, and eradicate H. pylori as well.
Functional dyspepsia
Recently, the “Rome III” classiﬁ  cation for functional 
gastrointestinal disorders was deﬁ  ned.84 In this classiﬁ  -
cation, functional dyspepsia (FD) is included in the 
subcategory of functional gastroduodenal disorders.85 
Four types of functional gastroduodenal disorders 
are distinguished: FD [B1, comprising postprandial dis-
tress syndrome (B1a) and epigastric pain syndrome 
(B1b)]; belching disorders (B2); functional nausea and 
vomiting disorders, functional vomiting, and cyclic 
vomiting syndrome (B3); and rumination syndrome 
(B4).85,86
Of patients with functional dyspepsia, 30%–60% 
carry H. pylori, but this prevalence is not much different 
from that in the unaffected population.87 Various stud-
ies have focused on the effect of H. pylori eradication 
in patients with both functional and uninvestigated dys-
pepsia. A meta-analysis of 13 randomized studies of 
nonulcer dyspepsia showed that when dyspepsia out-
comes are dichotomized into minimal/resolved versus 
same/worse symptoms, H. pylori eradication is associ-
ated with an 8% RR reduction compared with placebo.88 
The calculated number-needed-to-treat to cure one 
case of dyspepsia is 18. Apart from the focus on cure of 
symptoms, cost efﬁ  ciency is also an issue when treating 
large groups of patients. Given this reported number-
Table 2.  Gastric ulcer recurrence rate 1 year after H. pylori eradication
    Noneradication Eradication
    group group
Authors Year  %  (n) %  (n)  P value
Fukuda et al.72  1995 71  (42/59)    0  (0/24) <0.001
Seppala et al.75  1995 47  (60/128)    7  (2/29) <0.001
Sung et al.76  1995 58  (11/19)    8  (2/26) <0.001
Kato et al.73  1996 46  (18/39)    0  (0/11) <0.001
Axon et al.71  1997 48  (30/63)    7  (3/44) <0.001
Lazzaroni et al.74  1997 63  (20/32)  10  (2/20) <0.0016  H. Suzuki et al.: Consensus for H. pylori infection in Japan
needed-to-treat, it remains unclear whether H. pylori 
eradication is a cost-effective strategy. In a Canadian 
primary care study, however, H. pylori  eradication 
was reported to be more cost-effective after 1 year of 
follow-up than empirical diagnosis and treatment.89,90 In 
another interesting study, Sonnenberg and Townsend91 
found that, for some reason, expenditure on many other 
aspects of health care decreased after patients had erad-
icated H. pylori.
Another Cochrane meta-analysis compared treat-
ment strategies for uninvestigated dyspepsia.92  In-
dividual strategies consisted of initial pharmacological 
therapy (with endoscopy for treatment failures), early 
endoscopy, testing for H. pylori and endoscopy only for 
those testing positive, or H. pylori eradication therapy 
with or without prior testing. The analysis showed that 
proton-pump inhibitors (PPIs) are effective in the treat-
ment of dyspepsia. Early investigation by endoscopy or 
H. pylori testing beneﬁ  ted some patients with dyspepsia 
but was not cost-effective as part of an overall manage-
ment strategy.92 A meta-analysis of ﬁ  ve studies compar-
ing prompt endoscopy followed by targeted treatment 
versus an H. pylori test-and-treat strategy without fur-
ther investigation reported that endoscopy was associ-
ated with a small symptom beneﬁ  t at 1 year (RR, 0.95), 
but this strategy was not cost-effective.93 In summary, 
H. pylori play a role in the etiology of dyspeptic symp-
toms; thus, H. pylori test-and-treat strategies are effec-
tive for a subgroup of patients with dyspepsia. For 
patients with uninvestigated dyspepsia, an H. pylori 
test-and-treat strategy is an appropriate option, al-
though empirical acid-suppressive therapy can be more 
efﬁ  cient in populations with a low H. pylori prevalence. 
Also, in patients with investigated FD, H. pylori eradi-
cation is a relevant option. In both situations, patients 
must be aware that symptom resolution may take 
months after completion of therapy.
Atrophic gastritis, intestinal metaplasia, 
and gastric cancer
Thirty years ago, Correa et al.94 proposed that gastritis 
could progress to gastric cancer, which made the iden-
tiﬁ  cation of H. pylori as a major cause of gastritis even 
more relevant. Chronic H. pylori-induced inﬂ  ammation 
can eventually lead to loss of the normal gastric mucosal 
architecture, with destruction of gastric glands and 
replacement by intestinal metaplasia. This process of 
atrophic gastritis and intestinal metaplasia occurs in ap-
proximately half of the H. pylori-colonized population, 
ﬁ  rst in those subjects and at those sites where inﬂ  am-
mation is most severe.95 Because not everyone infected 
with H. pylori develops gastric cancer, several modiﬁ  ers 
have been identiﬁ  ed. Currently, the perception is that 
gastric cancer arises from multiple “hits,” which include 
oxidative stress and environmental toxins, which in-
crease mutation rates. Diet, bacterial factors, and genes 
regulating the host response likely affect the degree of 
oxidative stress and DNA damage.96  Host polymor-
phisms in the regions controlling interleukin (IL)-1 
have been reported to be associated with an increased 
incidence of hypochlorhydria and gastric cancer,97–102 
probably because these regions regulate the inﬂ  amma-
tory response to bacterial infections. Areas of gland loss 
and intestinal metaplasia extend with time multifocally, 
and although they do not give rise to any speciﬁ  c symp-
toms, they increase the risk for gastric cancer by ﬁ  ve- 
to 90-fold, depending on the extent and severity of 
atrophy.103
Evidence that H. pylori increases the risk of gastric 
cancer development via the sequence of metaplasia and 
atrophy originates from various studies that showed 
that H. pylori-positive subjects develop these conditions 
far more often than do uninfected controls.104 This ﬁ  nd-
ing is supported by data that show geographical associa-
tions between the prevalence of H. pylori  and the 
incidence of gastric cancer.105,106 On the basis of these 
ﬁ  ndings, it has been estimated that H. pylori coloniza-
tion increases the risk of gastric cancer approximately 
tenfold, and H. pylori  has been designated a class I 
carcinogen by WHO.107 Later case–control studies that 
looked more extensively into signs of previous H. pylori 
infection in gastric cancer patients and controls re ported 
even higher odds ratios, up to 68, for development of 
distal gastric cancer in the presence of H. pylori infec-
tion.108  This result is supported by data from animal 
models, most notably the Mongolian gerbil model, in 
which H. pylori infection induces atrophic gastritis and 
gastric dysplasia.60,61,109 The risk of development of atro-
phy and cancer in the presence of H. pylori is again re-
lated to host and bacterial factors, which inﬂ  uence the 
severity of the chronic inﬂ  ammatory response and the 
amount of gastric mucosa involved. As such, the risk 
is increased not only in subjects colonized with cagA-
positive strains110,111 but also in those with a genetic pre-
disposition to higher IL-1 production in response to 
colonization.97 In the developed world, 60% to 80% of 
gastric cancers are therefore related to the long-term 
presence of H. pylori.
Interestingly, the incidence of gastric cancer has sig-
niﬁ  cantly decreased over the past decades in Western 
countries. This decrease preceded the aforementioned 
decrease in the prevalence of H. pylori. As a slow pro-
cess over decades, however, this decrease is not relevant 
to an individual subject who is H. pylori-positive. Fur-
thermore, in spite of the decline in gastric cancer inci-
dence in Western countries, gastric cancer is still the 
fourth most common cancer in the world, as its incidence 
remains very high in large areas of the world, particu-
larly in parts of East Asia and South America.112 Much H. Suzuki et al.: Consensus for H. pylori infection in Japan  7
research now focuses on the cancer-preventive effect of 
H. pylori eradication, aimed at both the general popula-
tion and patients with preneoplastic conditions, particu-
larly atrophic gastritis and intestinal metaplasia. In the 
case of the latter, several placebo-controlled random-
ized studies have now reported that H. pylori eradica-
tion can induce to some extent regression of atrophy.113–117 
The effect of these interventions on gastric cancer pre-
vention is, however, less obvious than the historical can-
cer incidence might suggest. In several studies, H. pylori 
eradication had in the ﬁ  rst years of follow-up no signiﬁ  -
cant effect on gastric cancer incidence.114,116,118 In all of 
these studies, the difference between the eradication 
and placebo groups with respect to the incidence of gas-
tric cancer in the ﬁ  rst 4 to 12 years after treatment was 
not signiﬁ  cant. The striking observation in all of these 
studies, however, was that those gastric cancers that oc-
curred after eradication treatment were conﬁ  ned to 
those subjects who already had atrophic gastritis and in-
testinal metaplasia at baseline, suggesting that the major 
cancer-preventive effect of H. pylori eradication is to be 
expected in subjects without those precancerous condi-
tions; patients with those conditions may at least in part 
have already passed the point of no return. If conﬁ  rmed 
by other studies, this result means that the observed re-
gression of the severity of atrophy is of no direct rele-
vance with respect to cancer risk. One study differed 
from the others in that it did observe a signiﬁ  cant pre-
ventive effect of H. pylori eradication on gastric cancer 
development.119 The investigators monitored 1120 pa-
tients in a nonrandomized study for a mean of 3.4 years 
(range, 1–8 years) after H. pylori eradication treatment. 
Gastric cancer developed in 8 of 944 patients cured of 
infection and in 4 of 176 who had persistent infection (P 
= 0.04). The remarkable observation was that gastric 
cancers occurred only in patients with previous gastric 
ulcers and not in those who had duodenal ulcers (P = 
0.005).119 This result is consistent with the hypothesis 
that gastric ulcer patients, in contrast to duodenal ulcer 
patients, are characterized by reduced gastric acid secre-
tion, corpus-predominant gastritis, and accelerated 
progression toward atrophic gastritis and intestinal 
metaplasia. Similarly, previous studies have also shown 
that gastric ulcer patients are at higher risk for gastric 
cancer than are duodenal ulcer patients.26 The above-
mentioned preventive studies, taken together, described 
cancer development in 29 (1.5%) of 1896 subjects re-
ceiving placebo and in 25 (0.9%) of 2754 subjects receiv-
ing eradication treatment, corresponding to an odds 
ratio of 0.54 for cancer development after H. pylori 
eradication compared with placebo, suggesting that H. 
pylori eradication may decrease the risk for develop-
ment of distal gastric cancer. Further studies are being 
performed in this ﬁ  eld, the results of which will allow a 
more precise determination of the cancer-preventive 
effect of H. pylori eradication, of whether atrophy and 
metaplasia are conditions beyond the point of no return, 
and of the side effects and costs of such preventive 
measures.
The Japan Collaborative Cohort Study Group for 
Evaluation of Cancer Risk reported that women with a 
family history of gastric cancer and H. pylori infection 
were associated with a 5.1-fold greater risk for gastric 
cancer compared with women without a family history 
of gastric cancer and who did not have H. pylori infec-
tion.120 In contrast, family history and H. pylori infection 
were not found to be signiﬁ  cant risk factors for gastric 
cancer in male patients in their report, where the inves-
tigation of H. pylori infection was performed only by 
using H. pylori antibodies. Recently, results of a large 
nested case–control study within a prospective cohort 
have been reported in Japan.121 Among 123 576 subjects 
that were followed up from 1990 to 2004, 511 gastric 
cancer cases matched to 511 controls were used in this 
analysis. The adjusted odds ratio of gastric cancer asso-
ciated with H. pylori infection was 5.1. In addition, if 
anti-CagA positivity was used as an indicator of previ-
ous or current infection, the risk was reached 12.5.
Gastric MALT lymphoma
Nearly all MALT lymphoma patients are H. pylori posi-
tive,122  and  H. pylori-positive subjects have a signiﬁ  -
cantly increased risk for the development of gastric 
MALT lymphoma.123 Because of diagnostic controver-
sies and the relative rarity of this disorder, the exact in-
cidence in H. pylori-positive subjects is unknown, but 
MALT lymphomas occur in fewer than 0.1% of H. 
pylori-positive subjects.124 Randomized trials to deter-
mine the effect of H. pylori eradication in MALT lym-
phoma patients are therefore not feasible, but various 
case series have reported that eradication can lead to 
complete remission in patients with low-grade gastric 
MALT lymphoma.125–128 Overall, approximately 60%–
80% of these patients reach complete remission follow-
ing H. pylori eradication, some 10% continue to have 
signs of minimal residual disease, and the remainder 
show no response or disease progression. The variation 
in response among different series may be due in part 
to different criteria for the diagnosis of MALT lym-
phoma, potentially including some patients with benign 
lymphoid aggregates. Of those who initially reach com-
plete remission after H. pylori eradication, 10%–35% 
show recurrent disease during further follow-up. For 
that reason, long-term follow-up of MALT lymphoma 
patients is mandatory.129 A major predictor of the re-
sponse appears to be the presence of a t(11;18) (q21;q21) 
translocation. This translocation is associated with 
API2-MALT1  fusion, the former being involved in 
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caspase-like protein, with an as yet unknown biological 
function. Together, the fusion leads to suppression of 
apoptosis. Several studies have reported that MALT 
lymphomas with this translocation respond only rarely 
or not at all to H. pylori eradication.130,131
Gastroesophageal reﬂ  ux disease
Gastroesophageal reﬂ  ux disease (GERD) has long been 
considered to occur independently of H. pylori coloni-
zation; that is, it occurs with the same frequency and 
severity in H. pylori-positive and -negative subjects. 
This opinion is based on cross-sectional observations 
that suggest that the prevalence of H. pylori  among 
GERD patients is similar to that among controls.132 
However, further studies have suggested that H. pylori 
might protect against the development of GERD and 
by that means might be of beneﬁ  t to its hosts. This 
slowly emerging concept derives from repeated obser-
vations of a low prevalence of H. pylori among GERD 
patients, particularly of the more virulent strains;133 re-
ciprocal time and geographical trends for H. pylori 
prevalence compared with the incidence of GERD and 
its complications; a potentially increased incidence of 
GERD after H. pylori eradication;134 and the recogni-
tion that H. pylori-induced corpus gastritis reduces acid 
secretion. However, no evidence suggests that H. pylori 
eradication has a considerable impact on either the new 
development of GERD,135 the worsening of preexisting 
GERD when treatment has been withdrawn during dis-
ease remission,136  or preexistent GERD in remission 
during PPI maintenance therapy.113,117 Together, these 
data show that although epidemiologic data suggest that 
there may be an inverse relation between H. pylori 
and GERD, the risk for new development or worsening 
of preexistent GERD is not an issue when deciding 
whether to treat H. pylori.
Diagnosis of H. pylori infection
Diagnostic methods for H. pylori infection are catego-
rized as invasive or noninvasive tests.137 Invasive tests 
involve endoscopic biopsy of gastric mucosal samples, 
whereas noninvasive tests do not require an endoscopic 
procedure. The invasive tests are histology,138 rapid ure-
ase test (RUT),139 and microaerobic bacterial culture.17 
The advantage of the RUT is that it is inexpensive, easy-
to-use, and rapid. The advantages of culture are its 
speciﬁ  city of 100% (direct demonstration of the pres-
ence of H. pylori) and that it allows further character-
ization of the organism (determining its sensitivity to 
antibiotics, investigating its virulence factors, etc). Non-
invasive tests are the urea breath test,140 antibody tests 
of sera141–143 or of urine,144,145 and the H. pylori stool an-
tigen test.146–149
H. pylori eradication therapy
During the 20 years since the World Gastroenterology 
Organization (WGO-OMGE) consensus conference, 
international or domestic consensus conferences for H. 
pylori eradication have been held all over the world, 
including in Europe, America, and Asia (Fig. 4). Most 
recently, on 22 November 2006, the Japanese Society 
for Helicobacter Research held a “Current Consensus—
2006” (Management of H. pylori  infection in Japan) 
meeting in Tokyo. In this consensus meeting, one of the 
main topics was whether Japan will become the ﬁ  rst H. 
pylori-free country.
Originally, in 1988, Marshall et al.66 reported that H. 
pylori had been eradicated in 27% of a colloidal bis-
muth substrate (CBS)/placebo group and in 70% of a 
CBS/tinidazole group. Furthermore, when H. pylori 
persisted, 61% of duodenal ulcers healed and 84% re-
lapsed, whereas when H. pylori was cleared, 92% of 
ulcers healed and only 21% relapsed during the 12-
month follow-up period.66
According to a randomized, double-blind, placebo-
controlled study performed by Lind et al.,150  787 
patients with proven duodenal ulcer disease were ran-
domized to treatment twice daily for 1 week with 
omeprazole, 20 mg (O), plus either placebo (P) or com-
binations of two of the following antimicrobials: amoxi-
cillin, 1  g (A), clarithromycin, 250 or 500  mg (C250, 
C500), or metronidazole, 400 mg (M). Their eradication 
rates for the all-patients-treated analysis were 96%, 
OAC500; 95%, OMC250; 90%, OMC500; 84%, 
OAC250; 79%, OAM; and 1%, OP. These results sug-
gest that omeprazole-based triple therapies given twice 
daily for 1 week produce high eradication rates, are 
well-tolerated, and are associated with high patient 
compliance.
In terms of second-line treatment, Matsuhisa et al.151 
examined the eradication rate of a PPI, amoxicillin, and 
metronidazole (PPI/AM) regimen in 228 patients with 
H. pylori infection, in whom the ﬁ  rst-line therapy with 
a PPI, amoxicillin, and clarithromycin administered for 
1 week had failed. Their eradication rates for PPI/
AM(500) and PPI/AM(750) were 90.6% and 88.6%, 
respectively, suggesting that PPI/AM administered for 
1 week may be a highly effective second-line regimen.
In terms of third-line regimens, Gisbert et al.152 per-
formed a third eradication treatment with levoﬂ  oxacin 
(500  mg), amoxicillin (1  g), and omeprazole (20  mg), 
each twice daily for 10 days (n = 100), which resulted in 
per-protocol and intention-to-treat eradication rates of 
66% and 60%. Although such ﬂ  uoroquinolone-based 
rescue therapy constitutes an encouraging empirical 
third-line strategy after multiple previous H. pylori 
eradication failures,152 a high resistance rate (47.9%) to 
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from Japanese patients after unsuccessful  H. pylori 
eradication. Therefore, the choice of this antibiotic for 
the third-line treatment should be made only after drug 
susceptibility testing.153,154
Side effects and contraindications for 
H. pylori eradication
Side effects of H. pylori eradication are reported in up 
to 50% of patients taking the triple agent regimen.155,156 
The adverse effects are usually mild; fewer than 10% of 
patients stop treatment due to side effects.155 The com-
mon side effects are dysgeusia and diarrhea. Amoxicil-
lin can cause diarrhea or an allergic reaction with skin 
rash. Clarithromycin can cause dysgeusia, vomiting, 
nausea, abdominal pain, and rarely QT prolongation. 
Metronidazole can cause seizures, peripheral neuropa-
thy, and a disulﬁ  ram-like reaction with ethanol, and it 
can increase the toxicity of anticoagulants, lithium, and 
phenytoin. Acute gastrointestinal mucosal lesions have 
been demonstrated to be an adverse event after eradica-
tion therapy. Acute duodenal erosions were observed 
in 13.5% of patients who received eradication 
therapy;157 erosions were transient and asymptomatic in 
the early phase after eradication. Acute gastric erosions 
showed the same clinical characteristics, but acute gas-
tric ulcers with severe symptoms rarely occurred. The 
acute mucosal lesions that occurred were probably at-
tributable to an increase in acid secretion associated 
with the resolution of gastric mucosal inﬂ  ammation.6 
On the other hand, the occurrence of mild reﬂ  ux esoph-
agitis at a late phase after eradication is controversial. 
Helicobacter pylori infection is an environmental factor 
that has declined as GERD has increased.158 However, 
a systematic review159 of randomized trials did not show 
any role of H. pylori eradication in causing GERD. 
There was no increase in reﬂ  ux symptoms in almost 
3000 patients with H. pylori infection who were ran-
domly assigned eradication therapy compared with 
placebo.160,161 
Contraindications for H. pylori eradication are docu-
mented hypersensitivity to the eradication drugs, espe-
cially penicillin-allergy. However, alternative regimens 
such as bismuth/tetracycline/metronidazole combina-
tions can be used and exhibit high cure rates.
Future prospects
Interaction between gastric stem cells and H. pylori
Cells of the gastric mucosa undergo constant renewal, 
the rate depending on the health of the tissue. The cur-
rent evidence162 suggests that a single stem cell in every 
gastric gland indirectly gives rise to a clone of differenti-
ated cells, by production of committed progenitor cells. 
It is most likely that this stem cell occupies a niche in 
the isthmus composed of mesenchymal cells and extra-
cellular matrices. This environment regulates the 
function of the epithelial stem cell via mesenchymal–
epithelial cross talk. Recent studies in gnotobiotic 
mouse models of chronic atrophic gastritis163 have shown 
that parietal cell loss results in ampliﬁ  cation of multi- 
and oligopotential gastric stem cells, which express 
sialylated glycan receptors recognized by H. pylori ad-
hesions, SabA,164 HpaA,165 and HP0721.166 DNA micro-
array studies indicate that 6%–7% of H. pylori genes 
are differentially expressed in response to a shift in pH 
from 7 to 5.167 A large group of genes downregulated at 
pH 5, in particular, encode outer membrane proteins, 
including Hop family members that are predicted to be 
outer membrane porins and adhesins. Loss of acid-
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producing parietal cells increases bacterial adhesin ex-
pression and increases the proportion of stem cells with 
adhesin receptors.168  Another very provocative study 
suggests that in the mouse model of gastric cancer 
evoked with Helicobacter felis (cat Helicobacter), infec-
tion arises because malignant stem cells emerge from a 
pool of bone marrow cells that are recruited into areas 
of chronic gastritis.169
Other diseases of interest possibly inﬂ  uenced by 
H. pylori170
Idiopathic thrombocytopenic purpura (ITP) is an auto-
immune disease that leads to thrombocytopenia as a 
result of increased thrombocytolysis due to the appear-
ance of autoantibodies to platelets. The acute type fre-
quently occurs in children, often preceded by a viral 
infection. It develops rapidly and shows spontaneous 
remission. Chronic-type ITP occurs most commonly in 
adults and reportedly correlates with H. pylori infection. 
In 1988, Gasbarrini et al.7 reported that H. pylori eradi-
cation therapy to eight patients with H. pylori-positive 
ITP improved thrombocytosis after the therapy. Veneri 
et al.,171 who administered H. pylori eradication therapy 
to 43 patients with H. pylori-positive ITP, reported the 
therapy to be successful in 41 of the 43 and recognized 
continuous improvement in 20 (48.8%) of these 41 pa-
tients on long-term observation. According to another 
report by the same authors,172 the frequencies of HLA-
DRB 111, HLA-DRB 114, and HLA-DQB 103 as host 
factors were high in H. pylori-positive ITP, while the 
frequency of HLA-DRB 103 as a host factor was higher 
in the H. pylori-negative ITP group than in the H. 
pylori-positive ITP group, and HLA-DQB 103 showed 
favorable platelet reactivity after eradication therapy in 
H. pylori-positive ITP.172 Inaba et al.173 administered H. 
pylori eradication therapy to 35 patients with chronic 
ITP (25 H. pylori-positive ITP patients and 10 H. pylori-
negative ITP patients), and succeeded in eradicating the 
bacteria in all of the patients with H. pylori-positive ITP. 
They reported that the platelet count was improved in 
11 (44%) of the 25 patients, while the platelet count was 
unchanged in the 10 H. pylori-negative ITP patients. We 
also administered bacterial eradication therapy to 37 
patients with chronic ITP (26 H. pylori-positive ITP and 
11 H. pylori-negative ITP patients) and succeeded in 
eradicating the bacteria in all of the H. pylori-positive 
ITP patients; we found the platelet count to be im-
proved in 16 (62%) of the 26 patients with H. pylori-
positive ITP, while the platelet count was unchanged in 
the 11 patients with H. pylori-negative ITP.12 In other 
words, there was no improvement with bacterial eradi-
cation in H. pylori-negative ITP, and the effects of the 
antibacterial agent itself in terms of increasing the plate-
let count was negligible.
Many other reports show a relation between H. pylori 
infection and human diseases such as iron-deﬁ  ciency 
anemia8,174–181 and chronic urticaria.182–184
Final Message
While substantial progress has been made in our under-
standing of the role of genetic and environmental fac-
tors in the etiology of H. pylori-associated disease, there 
is still much to be learned about the epidemiology and 
pathogenesis of H. pylori. Although much knowledge 
of the potential association of H. pylori infection with 
human diseases has been accumulated, much of it is 
rather anecdotal or uncontrolled, and studies have not 
been consistently replicated in other centers. It is cer-
tainly true that further evidence-based studies should 
be performed to conﬁ  rm H. pylori associations and the 
beneﬁ  cial effects of eradication. On the other hand, 
eradication of H. pylori is rather simple these days and 
may be of no consequence in the treatment of patients 
with severe chronic diseases. In countries such as Japan 
where dreaded diseases such as gastric cancer seem to 
stem from H. pylori, the twenty-ﬁ  rst century may be the 
time to totally eradicate this troublesome organism 
from the entire population.
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